Agonist-dependent and -independent dopamine-1-like receptor signalling differentially regulates downstream effectors

Dirk Roosterman1

  • 1University Hospital Münster, Germany.

The FEBS Journal
|August 27, 2014
PubMed

Insights

The dopamine-5 receptor (D5R) shows high constitutive activity, impacting energy metabolism by increasing glucose breakdown and transporter expression. This suggests D5R

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Dopaminergic system dysregulation is implicated in neurological disorders like schizophrenia and bipolar disorder.
  • Constitutive receptor signaling's role in energy metabolism remains underexplored, despite potential therapeutic benefits of inverse agonists over neutral antagonists.

Purpose of the Study:

  • To investigate the impact of constitutive dopamine-1 receptor (D1R) and dopamine-5 receptor (D5R) signaling on downstream cellular targets.
  • To elucidate the mechanisms by which D5R constitutive activity influences energy metabolism and protein expression.

Main Methods:

  • Utilized transiently and stably transfected HEK293T cells to study D1R and D5R signaling.
  • Assessed Na+/H+ exchanger (NHE) activity and glucose degradation.
  • Quantified mRNA levels of key metabolic proteins (e.g., Na, K-ATPase, NHE isoforms) following agonist treatment.
  • Investigated the role of G protein-coupled receptor kinase 2 (GRK2) in D5R signaling.

Main Results:

  • High constitutive activity of D5R correlated with increased NHE activity and accelerated glucose degradation.
  • Increased transcription and translation of Na, K-ATPase-α3 and NHE-2 were observed due to constitutive D5R signaling.
  • Chronic agonist treatment elevated mRNA levels of Na,K-ATPase-α2, NHE-2, and NHE-3.
  • GRK2 regulated constitutive D5R activation of a cAMP response element-based reporter without altering cell-surface receptor levels.

Conclusions:

  • Constitutive D5R activity significantly influences cellular energy metabolism, affecting ion transport and glucose processing.
  • Agonist-induced D5R activity leads to distinct changes in gene expression compared to constitutive signaling.
  • D5R exhibits differential regulation of protein activity and expression based on its signaling state (constitutive vs. agonist-induced).

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.1K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.1K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K